Koninklijke Philips Nv (PHG) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
Koninklijke Philips Nv's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Koninklijke Philips Nv's ROA in the fourth quarter of 2025? Koninklijke Philips Nv achieved a return on average assets (ROA) of 3.33 % in its fourth quarter of 2025, this is above PHG's average return on assets of 2.15%. Koninklijke Philips Nvs assets during the 12 months ending in the fourth quarter of 2025 are valued at $30 billion
ROA has improved compared to -2.54% in the third quarter of 2025, due to net income growth.
However, within the Healthcare sector 173 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 3343.
: Peripheral artery disease (PAD) remains a significant health challenge, impacting millions of individuals globally. Current treatment modalities often necessitate multiple interventions, which can complicate patient management and increase procedural risks. Royal Philips has embarked on a clinical trial to evaluate an innovative therapeutic device that aims to streamline treatment for PAD. This article discusses the implications of the THOR IDE clinical trial in the context of advancing endovascular therapy for PAD.Peripheral artery disease is characterized by the narrowing of peripheral arteries, commonly in the lower limbs, leading to significant morbidity and impacting patients quality of life. Traditional treatment approaches often involve a combination of invasive methods such as angioplasty and atherectomy. Each intervention typically requires distinct devices, presenting challenges in procedural efficiency and patient outcomes.
Philips Unveils FDA-Approved LumiGuide Guidewire, Celebrating 1,000 Patients Treated Using Revolutionary 3D Device Guidance Technology Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global frontrunner in health technology, has made a significant leap in the realm of endovascular procedures with the introduction of its newly FDA-approved 160cm LumiGuide guidewire. This sophisticated device leverages the innovative Fiber Optic RealShape (FORS) technology, heralding a new era in minimally invasive surgeries.The groundbreaking technology was first utilized clinically in 2020 and has since demonstrated remarkable efficacy in a variety of complex vascular interventions. The milestone of the 1,000th patient treated using FORS technology was achieved during an intricate aortic aneurysm repair operation conducted by Professor Carlos Timaran, MD, a luminary in the field of advanced endovascular techniques. His expertise not only exemplifies the growing acceptance of this technology among medical professionals but also underlines its importance in enhancing patient outcomes.
Comment on PHG's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 3.33 % compared to prior year, due to annual net income growth of % to $1,004.64 million, and due to decline of value in Koninklijke Philips Nv's assets by -7.01 % to $30,177.28 million, compared to $30,177.28 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
